πŸŽ‰ Pharmidex at Olink’s Lunchtime Networking Event! πŸŽ‰
February 4, 2025

We are delighted to announce that Martin Barrett, Head of Business Development at Pharmidex, will be attending the Lunchtime Networking Event – Olink PEA Technology Transforming Healthcare:

"The Impact of Proteogenomics" today, February 4, 2025, at Bee House, Milton, Abingdon, UK.


This event is a fantastic opportunity to explore how proteogenomics is shaping the future of healthcare and drug discovery. 

Martin looks forward to meeting fellow professionals, exchanging insights, and expanding Pharmidex’s network to support innovation in drug development.


πŸ“ Event Details:

πŸ—“ Date: February 4, 2025

πŸ“Œ Location: Bee House, 140 Eastern Ave, Park Dr, Milton, Abingdon OX14 4SB


If you're attending, don’t hesitate to connect with Martin and discover how Pharmidex can help accelerate your drug discovery and development success!

#Pharmidex #Networking #Olink #Proteogenomics #DrugDiscovery #Innovation #Collaboration


July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. πŸ‘©‍πŸ”¬ πŸ‘¨‍πŸ”¬ Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: βœ… Bitter-tasting APIs βœ… Unpalatable excipients βœ… The success of taste-masking strategies βœ… Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
July 21, 2025
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. βœ… Human-relevant metabolism data βœ… Supports IND-enabling ®gulatory studies βœ… Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. πŸ“© Contact us to see how 8HUM can support your project.
More Posts